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Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism
Prophylaxis After Total Hip and Knee Replacement
A Systematic Review and Meta-analysis of Randomized Clinical Trials
Gulraj S. Matharu, DPhil; Setor K. Kunutsor, PhD; Andrew Judge, PhD; Ashley W. Blom, PhD; Michael R. Whitehouse, PhD
IMPORTANCE Patients undergoing total hip replacement (THR) and total knee replacement
(TKR) receive venous thromboembolism (VTE) pharmacoprophylaxis. It is unclear which
anticoagulant is preferable. Observational data suggest aspirin provides effective VTE
prophylaxis.
OBJECTIVE To assess the effectiveness and safety of aspirin for VTE prophylaxis after
THR and TKR.
DATA SOURCES A systematic review and meta-analysis was performed of randomized clinical
trials (RCTs), with no language restrictions, from inception to September 19, 2019, using
MEDLINE, Embase, Web of Science, Cochrane Library, and bibliographic searches. The
computer-based searches combined terms and combinations of keywords related to the
population (eg, hip replacement, knee replacement, hip arthroplasty, and knee arthroplasty),
drug intervention (eg, aspirin, heparin, clexane, dabigatran, rivaroxaban, and warfarin), and
outcome (eg, venous thromboembolism, deep vein thrombosis, pulmonary embolism, and
bleeding) in humans.
STUDY SELECTION This study included RCTs assessing the effectiveness and safety of aspirin
for VTE prophylaxis compared with other anticoagulants in adults undergoing THR and TKR.
The RCTs with a placebo control group were excluded. The searches and study selection were
independently performed.
DATA EXTRACTION AND SYNTHESIS This study followed PRISMA recommendations and
used the Cochrane Collaboration’s risk of bias tool. Data were screened and extracted
independently by both reviewers. Study-specific relative risks (RRs) were aggregated
using random-effects models. Quality of evidence was assessed using the Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) approach.
MAIN OUTCOMES AND MEASURES The primary outcome was any postoperative VTE
(asymptomatic or symptomatic). Secondary outcomes were adverse events associated
with therapy, including bleeding.
RESULTS Of 437 identified articles, 13 RCTs were included (6060 participants; 3466 [57.2%]
women; mean age, 63.0 years). The RR of VTE after THR and TKR was 1.12 (95% CI, 0.78-1.62)
for aspirin compared with other anticoagulants. Comparable findings were observed for deep
vein thrombosis (DVT) (RR, 1.04; 95% CI, 0.72-1.51) and pulmonary embolism (PE) (RR, 1.01;
95% CI, 0.68-1.48). The risk of adverse events, including major bleeding, wound hematoma,
and wound infection, was not statistically significantly different in patients receiving aspirin vs
other anticoagulants. When analyzing THRs and TKRs separately, there was no statistically
significant difference in the risk of VTE, DVT, and PE between aspirin and other anticoagulants.
Aspirin had a VTE risk not statistically significantly different from low-molecular-weight heparin
(RR, 0.76; 95% CI, 0.37-1.56) or rivaroxaban (RR, 1.52; 95% CI, 0.56-4.12). The quality of the
evidence ranged from low to high.
CONCLUSIONS AND RELEVANCE In terms of clinical effectiveness and safety profile, aspirin
did not differ statistically significantly from other anticoagulants used for VTE prophylaxis
after THR and TKR. Future trials should focus on noninferiority analysis of aspirin compared
with alternative anticoagulants and cost-effectiveness.
JAMA Intern Med. 2020;180(3):376-384. doi:10.1001/jamainternmed.2019.6108
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T otal hip replacement (THR) and total knee replace-ment (TKR) are common and effective interventions fordegenerative joint conditions, such as osteoarthritis.1
Venous thromboembolism (VTE) (deep vein thrombosis [DVT]
and pulmonary embolism [PE]) is an important cause of long-
term morbidity, represents a preventable cause of mortality,
and has substantial health care costs.2 All patients undergo-
ing joint replacement are at risk of VTE because of the dura-
tion of surgery and reduced perioperative mobility. To re-
duce VTE risk, almost all patients receive up to 35 days of
anticoagulation after surgery.3 Rates of VTE at 90 days after
THR and TKR are variable (up to 5% for DVT and up to 2% for
PE in anticoagulated patients).4
Anticoagulants for preventing VTE include simple oral
agents (aspirin), injectable agents (low-molecular-weight hep-
arin [LMWH]), and newer oral agents (dabigatran etexilate and
rivaroxaban). Aspirin is inexpensive, is easily administered, re-
quires no blood monitoring, and is well tolerated, with an ex-
cellent safety profile.5 Currently, aspirin is used off-label for
VTE prevention in both the United States and the United King-
dom. However, there are some concerns that the newer and
more expensive oral agents may have higher bleeding risks,
including major hemorrhage and wound problems.5 There-
fore, considerable debate remains about which agents should
be preferred given that clinical effectiveness must be bal-
anced against bleeding risk and cost.
Major efforts have been made by organizations to pro-
duce guidelines for preventing VTE that use a rigorous ap-
proach to evidence synthesis and formulating recommenda-
tions. These organizations include the American Academy of
Orthopaedic Surgeons (AAOS), the American College of Chest
Physicians (ACCP), and the UK National Institute for Health and
Care Excellence (NICE).6-8 The 2011 AAOS guideline, which was
based on a moderate level of evidence, recommended that pa-
tients undergoing THR or TKR should receive VTE prophy-
laxis (pharmacologic and/or mechanical).6 However, at that
time, the AAOS was unable to recommend for or against any
specific VTE prophylactic agents because of a lack of evidence.6
In 2012, the ACCP endorsed aspirin for VTE prophylaxis after
THR and TKR, with a grade of 1B (moderate evidence) com-
pared with no VTE prophylaxis, which is the same level of
evidence assigned to both injectable and newer oral agents
compared with no VTE prophylaxis.7 In 2018, the NICE rec-
ommended aspirin alone as an option for VTE prophylaxis
after TKR; however, after THR, patients require 10 days of
LMWH before receiving aspirin, or they may solely receive the
newer, more expensive oral agents or LMWH.8
Although observational data provide some support for as-
pirin as VTE prophylaxis after THR and TKR, good-quality ran-
domized clinical trials (RCTs) supporting aspirin use are
limited.4,5 However, a large RCT (n = 3424), not included in the
latest recommendations from the AAOS, ACCP, or NICE was
recently published9 in which all patients received 5 days of
rivaroxaban after THR and TKR before being randomized to
continue rivaroxaban or switch to aspirin.6-9 Given that this
trial9 has not been considered in any previous meta-analysis
to date, it may change the interpretation of existing data.
We assessed the clinical effectiveness and safety of aspirin
compared with other anticoagulants for VTE prophylaxis
after THR and TKR by performing a systematic review and
meta-analysis of RCTs.
Methods
Search Strategy and Selection Criteria
We performed a systematic review and meta-analysis of RCTs
using a predefined protocol as per the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)
recommendations.1 0 Two of us (G.S.M. and S.K.K.)
independently searched MEDLINE, Embase, Web of Science, and
Cochrane Library databases for relevant articles (from inception
to September 19, 2019). The computer-based searches combined
terms and combinations of keywords related to the population
(eg, hip replacement, knee replacement, hip arthroplasty, and
knee arthroplasty), drug intervention (eg, aspirin, heparin,
clexane, dabigatran, rivaroxaban, and warfarin), and outcome
(eg, venous thromboembolism, deep vein thrombosis, pulmonary
embolism, and bleeding) in humans, with no language
restrictions. All trials included in the recent NICE VTE prevention
guideline were also assessed for suitability.8 The search strategy
and specific terms used are listed in eTable 1 in the Supplement.
Two of us (G.S.M. and S.K.K.) independently screened titles and
abstracts of all initially identified studies according to the
selection criteria. Full-text articles of studies meeting the
selection criteria were retrieved. Reference lists of selected
studies and relevant review articles were manually searched for
relevant articles.
We included RCTs assessing the clinical effectiveness and
safety of aspirin for VTE prophylaxis compared with other
agents in adults (≥18 years) undergoing THR or TKR. Patients
had to be randomized to aspirin or another anticoagulant for
inclusion. Trials using hybrid VTE prophylaxis strategies in
which aspirin was 1 of 2 agents used (eg, an initial course of
LMWH before a longer course of aspirin) were included to re-
flect current practice.8,9,11 We excluded all other study types
(nonrandomized and observational studies) as well as RCTs
with a placebo control group. The primary outcome was any
Key Points
Question What is the effectiveness and safety of aspirin for
venous thromboembolism prophylaxis after total hip and knee
replacement?
Findings In this systematic review and meta-analysis of 13
randomized clinical trials (6060 participants), the risk of venous
thromboembolism after total hip and knee replacement was
not statistically significantly different when using aspirin
compared with other anticoagulants. Adverse events, including
major bleeding, wound hematoma, and infection, were not
statistically significantly different in patients receiving aspirin
compared with other anticoagulants.
Meaning The effectiveness and safety of aspirin did not appear to have
been statistically significantly different from other anticoagulants used
for venous thromboembolism prophylaxis after total hip and knee
replacement and hence remains an option for use.
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VTE event (including DVT and/or PE) after surgery, regardless
of whether the event was asymptomatic or symptomatic.
Secondary outcomes, where reported, included mortality, ma-
jor bleeding complications (including gastrointestinal tract and
cerebrovascular hemorrhage), other bleeding complications,
and wound complications (eg, hematoma and infection).
No limits were placed on study follow-up duration.
Data Extraction and Quality Assessment
The data extraction was conducted by 2 of us (G.S.M. and S.K.K)
independently. In cases of inconsistency, consensus was
reached by a third author (M.R.W.). A standardized prede-
signed data extraction form was used to obtain the relevant
data from each study, including design, baseline demo-
graphic characteristics, geographical location, numbers en-
rolled and randomized, allocation concealment, blinding,
VTE prophylaxis regimens (including dosage and duration),
outcomes of interest, and follow-up duration. In cases of mul-
tiple publications involving the same study, the most up-to-
date or comprehensive information was extracted.
Potential sources of bias in RCTs were assessed using the
Cochrane Collaboration’s risk of bias tool,12 which assesses
the following 7 possible sources of bias: random sequence
generation, allocation concealment, blinding of participants
and personnel, blinding of outcome assessment, incomplete
outcome data, selective reporting, and other bias. For each
individual domain, studies were classified as having low,
unclear, or high risk of bias.
Statistical Analysis
Summary measures are presented as relative risks (RRs) with
95% CIs. We used reported RRs, or we calculated risk esti-
mates for studies that reported raw counts. Heterogeneity was
assessed using the Cochrane χ2 statistic and the I2 statistic. Ran-
dom-effects models, which take into account heterogeneity
within and between studies, were used to combine RRs. Par-
allel analyses used fixed-effects models. The decision to use
random-effects or fixed-effects models was based on I2 quan-
tification of heterogeneity, as well as variability in the clinical
and methodological aspects of the studies, number of stud-
ies available for pooling, and study sample sizes.13,14 Study-
level characteristics—including geographical location, RCT de-
sign, allocation concealment, joint type (THR vs TKR), specific
thromboprophylactic agent, VTE end point (DVT vs PE), and
number of reported VTE events—were prespecified as charac-
teristics for assessment of heterogeneity, which was con-
ducted using stratified analysis and random-effects metare-
gression. Other characteristics explored post hoc included year
of publication, follow-up duration, modern VTE diagnostic
methods, type of VTE (symptomatic vs asymptomatic), use of
mechanical VTE prophylaxis, and types and doses of antico-
agulants reflecting modern practice. Potential for publication
bias was assessed through formal tests (Begg funnel plots and
Egger regression symmetry tests).15 We used the Grading of
Recommendations Assessment, Development, and Evalua-
tion (GRADE) approach to assess the quality of the body of evi-
dence based on study limitations, inconsistency of effective-
ness, imprecision, indirectness, and publication bias.16 A
statistical software program (Stata, version 14.2; StataCorp LLC)
was used for all analyses. The level of statistical significance
was set as P < .05, with 95% CIs also used. All statistical tests




The initial search identified 437 potentially relevant citations
(Figure 1). After screening titles and abstracts, 15 articles re-
mained for full-text assessment. Two were subsequently
excluded. Thirteen RCTs9,11,17-27 (summarized in Table 1 and
Table 2) met the meta-analysis inclusion criteria.
Study Characteristics
The 13 RCTs9,11,17-27 included 6060 participants (2969 aspirin
and 3091 comparator), 3466 of whom (57.2%) were women. The
mean age of participants was 63.0 years. Eleven trials17-27 were
open-label, and 2 trials9,11 were double-blinded. Seven
studies9,11,18,22-25 were from North America, 4 studies17,19,21,26
were from Asia, and 2 studies20,27 were from Europe. Partici-
pant age ranged from 21 to 86 years. Seven studies11,18,20,21,23,25,27
reported only on patients undergoing THR, 3 studies9,17,22 re-
ported on both patients undergoing THR and patients under-
going TKR, and 3 studies19,24,26 reported only on patients
undergoing TKR. The most common comparators were LMWH
(5 studies11,17,20,24,26) or rivaroxaban (3 studies,9,19,26 one of
which used an initial 5-day course of LMWH followed by 14 days
of rivaroxaban19). All studies9,11,17-27 reported VTE events. Eleven
studies9,11,17,19-26 reported specifically on DVT, and 9
studies9,11,17,18,20,22-25 reported specifically on PE.
Risk of Bias
Using the Cochrane Collaboration’s risk of bias tool,12 a total
of 11 trials17-27 had a high risk of bias, with each study having
between 1 and 4 of the 7 possible sources of bias (eFigure 1 in
Figure 1. PRISMA Flow Diagram
422 Excluded on the basis of title
and/or abstract
437 Potentially relevant citations identified
from MEDLINE, Embase, Cochrane, Web
of Science, NICE guideline, and reference
list of relevant studies
2 Articles excluded due to heterogeneous
population (trauma and elective surgery,
including nonhip surgery)
13 Articles included based on 13 unique studies
15 Full-text articles retrieved for more
detailed evaluation
NICE indicates UK National Institute for Health and Care Excellence; PRISMA,
Preferred Reporting Items for Systematic Reviews and Meta-analyses.
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the Supplement). Bias was most common in blinding of par-
ticipants and personnel followed by blinding of outcome as-
sessment and allocation concealment. Two studies9,11 had a
low risk of bias in all domains.
Primary VTE Outcomes
In the whole cohort, the pooled risk of VTE after THR and TKR
in patients receiving aspirin was not statistically significantly
different from the risk in patients receiving other anticoagu-
lants (RR, 1.12; 95% CI, 0.78-1.62) (Figure 2). There was evi-
dence of heterogeneity between the included studies (I2 = 63%;
95% CI, 33%-80%; P = .001), which was not explained by any
of the study-level characteristics evaluated (Figure 3). On ex-
clusion of the largest trial contributing data to the analysis
(based on a noninferiority study design),9 the pooled RR
remained the same (1.14; 95% CI, 0.77-1.70), with minimal
change in heterogeneity (I2 = 66%; 95% CI, 38%-82%; P = .001).
The pooled risk of DVT (11 studies9,11,17,19-26) (RR, 1.04; 95% CI,
0.72-1.51) and PE (9 studies9,11,17,18,20,22-25) (RR, 1.01; 95% CI,
0.68-1.48) after THR and TKR in patients receiving aspirin
also were not statistically significantly different compared
with patients receiving other anticoagulants.
Adverse Events
There was variable reporting of adverse events among the
studies. The most common adverse event reported was wound
hematoma (5 studies20,21,23,25,27) followed by major bleeding
(3 studies9,11,23), wound infection (3 studies9,11,23), and other
wound complications (3 studies19,22,26). In the pooled analysis,
the risks of the following events were not statistically signifi-
cantly different in patients receiving aspirin vs other anticoagu-
lants: any bleeding, major bleeding, minor bleeding, gastroin-
testinaltractbleeding,woundhematoma,woundinfection,other
wound complications, myocardial infarction, and death (eFig-
ure 2 in the Supplement). Patients receiving aspirin had a
statistically significantly reduced pooled risk of bruising (RR,
0.68; 95% CI, 0.54-0.84) and lower limb edema (RR, 0.57; 95%
CI, 0.37-0.88) compared with those receiving comparators.
Subgroup Analysis
Because of limited data, subgroup analysis only assessed the pri-
mary outcome of interest (VTE). There was no evidence of ef-
fect modification by any of the clinically relevant study-level
characteristics explored (Figure 3). Specifically, the type of joint
surgery (THR vs TKR) and thromboprophylactic agent did not
alter the risk of VTE. In the 5 studies11,17,20,24,26 reporting on VTE
in patients receiving LMWH, the risk of VTE was not statisti-
cally significantly different in patients receiving aspirin vs
LMWH (RR, 0.76; 95% CI, 0.37-1.56). The risks of DVT (RR, 0.83;
95% CI, 0.42-1.63) and PE (RR, 0.71; 95% CI, 0.19-2.61) were also
not statistically significantly different. In the 3 studies9,19,26 re-
porting on VTE events in patients receiving aspirin compared
with rivaroxaban (with or without an initial course of LMWH),
the risks of VTE (RR, 1.52; 95% CI, 0.56-4.12) and DVT (RR, 1.67;
95% CI, 0.53-5.26) were also not statistically significantly
different. Further subgroup analyses by study-level character-
istics, such as year of publication, follow-up duration, modern
VTE diagnostic methods, type of VTE, types and dosages of
anticoagulants reflecting modern practice, and equal distribu-
tion of mechanical VTE prophylaxis, did not demonstrate any
evidence of effect modification.
Publication Bias
For comparisons involving 10 or more studies, visual inspec-
tion of Begg funnel plots for studies of VTE and DVT were sym-
metrical (eFigure 3 in the Supplement). These were also con-
sistent with Egger regression symmetry tests, demonstrating
no statistically significant evidence of publication bias.
GRADE Ratings
GRADE ratings for outcomes involving pooled analyses of 5 or
more studies were assessed (eTable 2 in the Supplement). The
quality of evidence for VTE, DVT, PE, and wound hematoma
ranged from low to high.







Age, mean (range), y 63 (21-86)
Female, No. (%) 3466 (57.2)
Joint replacement population
Both THR and TKR 3 Studies9,17,22 (n = 3857)
THR only 7 Studies11,18,20,21,23,25,27
(n = 1495)
TKR only 3 Studies19,24,26 (n = 708)
Geographical location




Europe 2 Studies20,27 (n = 172)
Comparatora
Rivaroxaban with or without LMWH 3 Studies9,19,26 (n = 1879)
LMWH 5 Studies11,17,20,24,26
(n = 747)
Warfarin sodium 3 Studies22,23,25 (n = 258)
LMW dextran 4 Studies18,21,23,27
(n = 173)








Follow-up duration for outcome assessment,
range (when specified)
9 d to 6 mo
Abbreviations: DVT, deep vein thrombosis; LMW, low-molecular-weight;
LMWH, low-molecular-weight heparin; PE, pulmonary embolism; THR, total hip
replacement; TKR, total knee replacement; VTE, venous thromboembolism.
a Studies could report on more than 1 comparator vs aspirin. Two studies23,26
reported on more than 1 comparator vs aspirin (see Table 2 for details).
b Studies could report on more than 1 outcome. All but 2 studies21,27 reported
on 2 or more outcomes from VTE, DVT, and PE.
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Discussion
This systematic review and meta-analysis of RCTs demon-
strated that there was no statistically significant difference in
the risk of VTE (including DVT and PE) when comparing aspi-
rin with other anticoagulants for VTE prophylaxis in patients
undergoing THR and TKR. The findings for VTE remained con-
sistent when patients undergoing THR and TKR were as-
sessed separately as well as when comparing aspirin with other
commonly used anticoagulants, including LMWH and rivar-
oxaban. There were no differences in the risk of adverse events,
such as bleeding, wound complications, myocardial infarc-
tion, and death, when aspirin was compared with other anti-
coagulants, although patients receiving aspirin had a reduced
risk of bruising and lower-limb edema. Findings for adverse
events were based on data reported by few studies, and some
of the estimates were imprecise; therefore, caution is needed
when interpreting these results. In addition, RCTs were hetero-
geneous in terms of populations studied (THR and/or TKR) and
anticoagulants compared with aspirin (specific drug and dos-
age). However, formal subgroup analyses confirmed that the
main study findings were not modified by study-level charac-
teristics, including geographical location, RCT design, alloca-
tion concealment, type of surgery (THR vs TKR), specific throm-
boprophylactic agent, VTE end point (DVT vs PE), number of
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Abbreviations: DVT, deep vein thrombosis; IPC, intermittent pneumatic compression; LMW, low-molecular-weight; LMWH, low-molecular-weight heparin;
NS, not specified; THR, total hip replacement; TKR, total knee replacement; VTE, venous thromboembolism.
Figure 2. Effectiveness of Aspirin Compared With Other Anticoagulants on Venous Thromboembolism (Including Deep Vein Thrombosis




















100.00Random effects 1.12 (0.78-1.62)
Fixed effects 1.11 (0.99-1.25)
5.8918 110 1023Zou et al,26 2014 5.56 (1.69-18.33)
10.8726 43 449Harris et al,18 1985 2.96 (1.57-5.55)
5.106 50 503Kim et al,21 1998 2.00 (0.53-7.56)
11.7924 129 13519Westrich et al,24 2006 1.32 (0.76-2.29)
7.218 72 696Woolson et al,25 1991 1.28 (0.47-3.49)
15.87131 166 146106Lotke et al,22 1996 1.09 (0.96-1.23)
6.095 40 425Josefsson et al,20 1987 1.05 (0.33-3.35)
6.876 43 436Salzman et al,23 1971 1.00 (0.35-2.86)
8.9111 1707 171712Anderson et al,9 2018 0.92 (0.41-2.08)
9.2910 60 6011Jiang et al,19 2014 0.91 (0.42-1.98)
7.104 61 6018Gelfer et al,17 2006 0.22 (0.08-0.61)
2.451 380 3985Anderson et al,11 2013 0.21 (0.02- 1.78)
2.561 30 305Alfaro et al,27 1986 0.20 (0.02-1.61)
Thirteen randomized clinical trials9,11,17-27 were included. Outcomes included
both symptomatic and asymptomatic venous thromboembolism events. The
summary estimate presented was calculated using a random-effects model.
Sizes of data markers are proportional to the inverse of the variance of the
relative ratio. RR indicates relative risk. The diamonds represent the overall
estimated relative risk (with 95% CIs) for the 13 trials combined when using a
random-effects model and when using a fixed-effects model.
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reported VTE events, publication year, type of VTE (sympto-
matic vs asymptomatic), types and doses of anticoagulants re-
flecting modern practice, modern VTE diagnostic methods, use
of mechanical VTE prophylaxis, and follow-up period. The qual-
ity of the evidence ranged from low quality to high quality for
the primary outcomes of VTE and/or DVT and PE and for the
most commonly reported complication of wound hematoma.
Our findings are consistent with large observational
cohorts,4,5,28-31 which have reported that aspirin was effective
for VTE prophylaxis and that aspirin had a similar or slightly im-
proved effectiveness and safety profile compared with other
commonly used anticoagulants. Therefore, we believe current
evidence supports the continued use of aspirin in VTE prophy-
laxis after THR and TKR.
Figure 3. Effectiveness of Aspirin Compared With Other Anticoagulants on Venous Thromboembolism (VTE) in Randomized Clinical Trials
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RCT design
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23911 804 781191Open label17-27 1.20 (0.81-1.78)
Joint type
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Follow-up duration, d
23310 2728 2731189≥149,11,17-19,21,22,24-26 1.16 (0.75-1.79)
173 133 13514<1420,23,27 1.21 (0.62-2.38)
Modern VTE diagnosis
23910 2778 2781192Yes9,11,17-19,21,22,24-26 1.20 (0.79-1.81)
123 113 11516No20,23,27 0.83 (0.39-1.75)
VTE end point
18111 2848 2852155DVT9,11,17,19-26 1.04 (0.72-1.51)
469 2641 265443PE9, 11,17,18,20,22-25 1.01 (0.68-1.48)
Type of VTE
183 2130 215823Symptomatic9,11,23 0.84 (0.45-1.55)
23310 761 738185Asymptomatic17-22,24-27 1.22 (0.79-1.87)
Regimen comparison
393 1877 197826Aspirin vs rivaroxaban9,19,26 1.52 (0.56-4.12)
525 720 74761Aspirin vs LMWH11,17,20,24,26 0.76 (0.37-1.56)
Mechanical VTE prophylaxis
586 2008 202353Distributed equally between
groups9,18-20,24,25
1.12 (0.79-1.59)
1937 883 873155None11,17,21-23,26, 27 1.07 (0.56-2.07)
Type/doses of anticoagulants
686 2447 247268Reflecting modern
practice9,11,17,19,24,26
0.91 (0.43-1.93)
1837 444 424140Others18,20-23,25,27 1.32 (0.84-2.06)
No. of VTE events
2247 2276 2264178≥209,17-19,22,24,26 1.22 (0.76-1.98)














Thirteen randomized clinical trials9,11,17-27 were included. Outcomes included both symptomatic and asymptomatic VTE events. P values are for meta-regression.
DVT indicates deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RCT, randomized clinical trial; RR, relative risk; THR, total hip
replacement; and TKR, total knee replacement.
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The inclusion of a recent RCT9 in this meta-analysis was im-
portantgiventhatitwaslarge,representedoneofonly2studies9,11
appraised that had a low risk of bias,9 and was one of only a few
studies9,19,26 comparing the newer oral anticoagulants (eg, riva-
roxaban) with aspirin, albeit after an initial 5-day course of riva-
roxabanforallpatients.Furthermore,thisRCT9 hasnotbeencon-
sidered in any previous evidence synthesis to date and thus could
change the interpretation of existing data. The authors of the trial
observed no difference in the risk of VTE or adverse events be-
tween aspirin and rivaroxaban. That single trial comprised more
than half of the patients included in our systematic review and
meta-analysis. However, analyses excluding that large trial also
demonstrated that aspirin was not statistically significantly dif-
ferentfromLMWH,whichisanalternativecurrentmethodofVTE
prophylaxis frequently used worldwide.
We consider the current evidence on VTE prophylaxis
after THR and TKR to be more in line with the recommenda-
tions from the ACCP7 rather than the NICE,8 with the latter
still not recommending aspirin monotherapy after THR,
despite supportive evidence provided herein and from other
studies.5,29 However, given that most current trials17-27
included in our study had a high risk of bias, we still require
robust data from large well-designed RCTs to explore the effi-
cacy, safety, and cost-effectiveness of aspirin compared with
other commonly used anticoagulants. A current RCT in North
America will randomize 25 000 patients undergoing THR and
TKR either to aspirin, warfarin sodium, or rivaroxaban to
determine the efficacy and safety of each drug for VTE
prophylaxis32; however, that study does not include com-
monly used anticoagulant agents, such as dabigatran and
LMWH. It is acknowledged that some VTE prophylactic
agents are becoming less popular in certain regions or coun-
tries because of potential drawbacks compared with aspirin
and direct oral anticoagulants. For example, LMWH requires
daily injections administered by either the patient or health
care professionals, and warfarin requires regular blood testing
to ensure therapeutic levels of anticoagulation, with poten-
tially life-threatening consequences if patients are excessively
anticoagulated.
Strengths and Limitations
This study has several strengths. The present systematic re-
view and meta-analysis is the first to include the largest RCT9
to date in this area, thus providing the most comprehensive
update on the effectiveness and safety of aspirin for VTE pro-
phylaxis after THR and TKR. We have used a detailed and ro-
bust search strategy that spanned multiple databases and was
without language restriction. This allowed us to include trials
from all over the world, improving the generalizability of our
findings. Only RCTs were included; therefore, by excluding
observational studies, we removed the inherent selection bias
associated with this study design. A detailed assessment of
methodological quality of the included studies was per-
formed. We systematically explored for sources of heteroge-
neity using several study-level characteristics and tested for
evidence of effect modification. Notably, we stratified our
analyses for patients undergoing THR and TKR and com-
pared aspirin with specific anticoagulants, which have been
limitations of previous trials and systematic reviews. Our re-
sults remained robust in several sensitivity analyses, and for-
mal testing demonstrated no evidence of publication bias.
There were several limitations, with most inherent to the
meta-analysis. The analysis was limited by the few relevant
RCTs9,11,17-27 that have been published and small sample sizes
giventheoutcomesofinterest.Thelowadverseeventrateinsome
trials led to wide 95% CIs around the RRs, thus reducing the pre-
cisionoftherespectiveestimates.Moststudies17-27 hadahighrisk
of bias in at least 1 domain. Furthermore, there was variability in




follow-up duration. These factors potentially could have led to
biased estimates, despite being assessed in sensitivity analyses.
There appeared to be selective reporting on adverse events be-
cause these data were not reported by some of the included stud-
ies, which could have led to loss of power to demonstrate if any
associations existed. There was statistically significant hetero-
geneity among the studies9,11,17-27 that could not be explained by
several relevant study-level characteristics, suggesting that other
factors might be responsible. It is acknowledged that there is bias
toward overreporting symptomatic DVT in the trials17-22,24-27 that
routinely screened for asymptomatic DVT given that the latter is
frequently treated when identified. In addition, a large RCT9 con-




Available evidence from RCTs suggests that in terms of clinical
effectiveness and safety, aspirin is not statistically significantly
different from other anticoagulants used for VTE prophylaxis
after THR and TKR. The body of evidence ranges from low qual-
ity to high quality. However, given that most of the relevant
currenttrialevidencehasahighriskofbias,additional large,well-
designed RCTs are needed to validate these findings. Further-
more, these trials must determine whether newer, more expen-
sive anticoagulants (including rivaroxaban and dabigatran) have
any clinical benefit over aspirin for VTE prophylaxis after THR
and TKR and whether these drugs are cost-effective.
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